KIEs in OxidatiVe Cyclization of ProclaVaminic Acid
J. Am. Chem. Soc., Vol. 121, No. 49, 1999 11365
and the mixture was stirred at 40 °C under argon for 41 h. The mixture
was filtered through a pad of silica gel washing with benzene to remove
the cinchonine, the filtrate concentrated in vacuo, and the residue applied
to a column of silica gel (60 g, benzene). The column was eluted with
benzene until thiophenol was no longer detected in the eluent, and
elution was continued with ethyl acetate to recover the desired product.
Concentration in vacuo gave a white solid, which when recrystallized
from benzene/cyclohexane and methylene chloride/petroleum ether,
gave optically pure 29 (3.724 g, 20.77 mmol, 29%) as white needles
and optically impure product (8.342 g, 46.54 mmol, 65%) as white
plates. The optically pure material gave the following physical and
spectral data: mp 68-69 °C [lit.25 mp 58-60 °C]; [R]D ) -137° (c
425.1713; Anal. Calcd for C29H30N2O5S: C 65.15, H 5.66, N 5.24, S
6.00; found: C 65.00, H 5.61, N 5.18, S 5.90.
Benzyl (2R,3R)-[2-14C]-5-(N-Benzyloxycarbonyl)-amino-3-hydroxy-
2-(2′-oxoazetidin-1′-yl)pentanoate (32). Thiophenyl â-lactam 31 (48.8
mg, 0.091 mmol), tris(trimethylsilyl)silyl hydride (75 µL, 0.24 mmol),
and AIBN (∼5) were disolved in dry, distilled benzene (4 mL) and
the solutionwas degassed by bubbling Ar for 30 min. The reaction
mixture was brought to reflux with stirring. Additions of tris-
(trimethylsilyl)silyl hydride (3 × 75 µL) and AIBN (3 × 5 mg) were
made over the next 15 h, and the reaction was terminated after 19 h.
The benzene was removed in vacuo and the residue purified via radial
chromatography (1 mm silica gel; ethyl acetate:hexane, 1:4 to 100%
ethyl acetate), giving 26.3 mg (0.062 mmol, 68%) of the desired product
as a colorless oil. Radioinactive and nondeuteriated material prepared
similarly gave the following physical and spectral data: [R]D ) -24°
1
) 1.0, CHCl3) [lit.25 [R]D ) -105°]; H NMR (CDCl3) δ 7.49-7.37
(m, 5H, ArH), 6.27 (b, 1H, NH), 5.03 (dd, J ) 2.4, 4.9 Hz, 1H, H-4),
3.40 (ddd, J ) 1.9, 5.0, 15.3 Hz, 1H, H-3), 2.96 (dd, J ) 2.4, 15.3 Hz,
1H, H-3); 13C{1H} NMR (CDCl3) δ 166.1, 133.4, 131.3, 129.3, 128.6,
54.2, 45.4; MS m/z 179 (M+, 7%), 119, 110, 77, 70 (100%); accurate
mass 179.0406, calcd for C9H9NOS 179.0405.
1
(c 1.7, CHCl3); H NMR (CDCl3) δ 7.36 (m, 10H, ArH), 5.22 (ABq,
J ) 12.0 Hz, 2H, CH2Ph), 5.16 (bs, 1H, NH), 5.09 (s, 2H, CH2Ph),
4.65 (bs, 1H, OH), 4.18 (m, 1H, H-3), 4.08 (br, 1H, H-2), 3.43 (m,
1H, H-5), 3.32 (m, 2H, H-4′), 3.25 (m, 1H, H-5), 2.95 (t, J ) 4.0 Hz,
2H, H-3′), 1.87 (m, 1H, H-4), 1.78 (m, 1H, H-4); 13C{1H} NMR
(CDCl3) δ 168.5, 168.0, 156.8, 136.4, 135.0, 128.5, 128.3, 128.1, 127.9,
127.8, 69.1, 67.1, 66.5, 61.7, 39.6, 37.8, 36.2, 33.4; MS m/s 219, 148,
128, 108, 91 (100%), 79, 65; accurate mass 426.1799, calcd for
C23H26N2O6 426.1791.
Benzyl [2-14C]-(4′S)-(4′-thiophenyl-2′-oxoazetidin-1′-yl) acetate
(30). A solution of azetidinone (-)-29 (161.8 mg, 0.9027 mmol) in
THF (13 mL) was cooled to -78 °C, and a solution of LiHMDS (950
µL, 1.0 M in hexane) was added dropwise via syringe in 5 min. After
50 min, [2-14C]-methyl bromoacetate (196.1 mg, 0.8561 mmol) in THF
(5 mL) was added dropwise via syringe over 10 min. The reaction
was warmed to -20 °C over 45 min and stirred for 1 h at -20 °C.
After the reaction was quenched with a solution of acetic acid in THF,
ethyl acetate (100 mL) was added, and the mixture was washed with
1 N HCl (100 mL), 5% NaHCO3 (100 mL) and saturated brine (2 ×
100 mL). The organic layer was dried (anhydrous Na2SO4) and
concentrated in vacuo, and the residue was purified by radial chroma-
tography (1 mm silica gel; ethyl acetate:hexane, 1:19 to 1:1) to give
the desired product (131.3 mg, 0.4011 mmol, 47%) as a colorless oil.
Radioinactive material prepared similarly gave the following spectral
data: [R]D ) +98.5° (c 0.72, CHCl3) IR (CHCl3) 3016, 1767, 1405,
Benzyl (2S,3R)-[2-14C]-5-(N-Benzyloxycarbonyl)-amino-3-hydroxy-
2-(2′-oxoazetidin-1′-yl)pentanoate (33). To D-erythro diastereomer 32
(26.3 mg, 0.062 mmol) in CH2Cl2 (4 mL) was added DBN (10 µL,
0.08 mmol), and the reaction was stirred for 1 h. Silica gel (∼500 mg)
was added to terminate the reaction, and the mixture filtered through
a pad of silica gel, washing with ethyl acetate. The filtrate was
concentrated in vacuo to give 22.0 mg (0.052 mmol, 84%) of the
protected proclavaminic acids in ratio of > 4:1 favoring the desired
(2S,3R) (threo) diastereomer. Radioinactive and nondeuteriated mate-
rial prepared similarly gave the following physical and spectral data:
1
1
1387, 1345, 1260, 1230, 1188, 941 cm-1; H NMR (CDCl3) δ 7.41-
[R]D ) +22.3° (c 0.85, CHCl3); H NMR (CDCl3) δ 7.33 (m, 10H,
7.28 (m, 10H, ArH), 5.22 (dd, J ) 2.3, 5.1 Hz, 1H, H-4′), 5.11 (ABq,
J ) 12.1 Hz, 2H, CH2Ph), 4.32 (ABq, J ) 18.2 Hz, 1H, H-2), 3.78
(ABq, J ) 18.2 Hz, 1H, H-2), 3.18 (dd, J ) 5.1, 15.2 Hz, 1H, H-3′â),
2.88 (dd, J ) 2.3, 15.2 Hz, 1H, H-3′R); 13C{1H} NMR (CDCl3) δ 167.7,
165.3, 134.8, 133.8, 130.1, 129.3, 128.7, 128.6, 128.5, 67.3, 58.9, 36.6,
41.1; MS m/z 327(M+, 0.3%), 218 (M+ - SPh, 9%), 181, 176, 135,
109, 91 (100%); accurate mass 327.0931, calcd for C18H17NO3S,
327.0929.
ArH), 5.22 (ABq, J ) 12.0 Hz, 2H, CH2Ph), 5.13 (br, 1H, NH), 5.07
(s, 2H, CH2Ph), 4.47 (d, J ) 8.2 Hz, 1H, OH), 4.27 (m, 1H, H-3), 4.14
(d, J ) 3.1 Hz, 1H, H-2), 3.44 (m, 3H, H-5 and H-4′), 3.28 (m, 1H,
H-4′), 3.00 (t, J ) 4.0 Hz, 2H, H-3′), 1.68 (m, 2H, H-4); 13C{1H} NMR
(CDCl3) δ 169.3, 168.5, 157.1, 136.3, 135.1, 128.6, 128.5, 128.3, 128.2,
128.1, 128.0, 68.9, 67.4, 66.8, 61.8, 40.3, 37.7, 36.3, 34.4; MS m/z
219, 148, 128, 108, 91 (100%), 79, 65; accurate mass 426.1799, calcd
for C23H26N2O6 426.1791.
(2S,3R)-[2-14C]-Proclavaminic Acid (34). Hydrogenation of dia-
stereomer 33 (22.0 mg, 0.052 mmol) in ethanol (4 mL) containing 10%
Pd/C (∼5 mg) by bubbling hydrogen through the Ar degassed solution
for 30 min with stirring. The catalyst was removed by filtration and
the filtrate concentrated to approximately 0.5 mL in vacuo. The material
was purified twice via reverse phase HPLC, first using a Partisil ODS-3
C-18 column, then using a Spheresorb S5 ODS-2 C-18 column, both
with H2O as eluent. Radioinactive and nondeuteriated material prepared
in a similar manner gave the following physical and spectral data: mp
153-154 °C; [R]D ) +6.85° (c 0.35, H2O) [lit.23 +7.3° (c ) 1.0, H2O)];
Benzyl (2R,3R,4′S)-[2-14C]-5-(N-Benzyloxycarbonyl)-amino-3-hy-
droxy-2-(4′-thiophenyl-2′-oxoazetidin-1′-yl)pentanoate (31). Azeti-
dinone 30 (131.3 mg, 0.4011 mmol) in THF (10 mL) was cooled to
-78 °C, a solution of LHMDS (480 µL, 1.0 M in hexane) was added
dropwise via syringe and the reaction stirred for 2 h. Cbz-aldehyde
22b (202.9 mg, 0.9791 mmol) in THF (3 mL) was then added dropwise
and the mixture stirred a further 2 h. After the reaction was quenched
by the addition of acetic acid in THF, the mixture was diluted with
ethyl acetate (70 mL) and washed with 1 N HCl (50 mL), 5% NaHCO3
(50 mL), and saturated brine (50 mL). The organic layer was dried
(anhydrous Na2SO4) and concentrated in vacuo, and the residue was
purified via radial chromatography (2 mm silica gel; ethyl acetate:
hexane, 1:19 to 1:1), to give the starting azetidinone 30 (25.0 mg, 0.076
mmol, 19%), and the desired D-erythro 31 (59.1 mg, 0.111 mmol, 28%)
as a white solid. Recrystallization from ethyl acetate/cyclohexane
provided the product as fine, white needles (48.8 mg, 0.091 mmol,
23%), with a specific activity of 1.22 mCi/mmol. Radioinactive and
nondeuteriated material prepared similarly gave the following physical
and spectral data: mp 102-103 °C; [R]D ) +73 ° (c 1.4, CHCl3); IR
(CHCl3) 3446, 3006, 2950, 1748, 1735, 1509, 1261, 1233, 1216, 1188,
1
IR (KBr) 3373, 2940, 1703, 1634, 1378, 773 cm -1; H NMR (D2O/
acetone) δ 4.15 (ddd, J ) 3.9, 5.5, 9.4 Hz, 1H, H-4′), 4.00 (d, J ) 5.5
Hz, 1H, H-2), 3.50 (m, 1H, H-4′), 3.43 (m, 1H, H-4′), 3.07 (m, 2H,
CH2NH2), 2.93 (t, J ) 4.0 Hz, 2H, H-3′), 1.89 (m, 2H, H-4); 13C{1H}
NMR (D2O/dioxane) δ 175.3, 173.2, 70.0, 63.5, 41.2, 38.1, 36.2, 32.0;
CI-MS m/z 203 (MH+, 100%), 185, 167, 143, 115; accurate mass
(MH+) 203.1037, calcd for C8H15N2O4 203.1037.
Synthesis of (2S,3R 3′-2H2,4,5-3H]-Proclavaminic Acid (42). [2,3-
3H]-N-benzyloxycarbonyl-3-aminopropanol (22a). To NaHCO3 (377.1
mg, 4.489 mmol) and â-alanine (181.0 mg, 2.032 mmol) in a 50 mL
flask was added a solution of [2,3-3H]-â-alanine (5 mCi) in 5 mL of
0.01 N HCl followed by H2O washings (5 mL) and dioxane (7.5 mL).
The solution was cooled in an ice bath, and benzyl chloroformate (450
µL, 3.15 mmol) dissolved in dioxane (2.5 mL) was added in
approximately 15 min. The mixture was stirred for 45 min, warmed to
room temperature, and stirred a further 3 h. The dioxane was removed
in vacuo, and the resulting solution was transferred to a separatory
funnel, diluted with 5% NaHCO3 (30 mL), and washed with ethyl
1
1040 cm-1; H NMR (CDCl3) δ 7.36-7.28 (m, 15H, ArH), 5.21 and
5.12 (ABq, J ) 11.2 Hz, 2H, CH2Ph), 5.11 (s, 2H, CH2Ph), 5.22 (bs,
1H, NH), 4.96 (bs, 1H, OH), 4.88 (dd, J ) 2.4, 5.1 Hz, 1H, H-4′),
4.20 (m, 1H, H-3), 3.99 (bs, 1H, H-2), 3.45-3.31(m, 2H, H-5), 3.34
(dd, J ) 5.1, 15.4 Hz, 1H, H-3′â), 2.89 (dd, J ) 2.1, 15.3 Hz, 1H,
H-3′R), 2.05-1.88 (m, 2H, H-4); MS m/z 425 (M+ - SPh, 2.2), 407
(M+ - SPh - H2O), 383 (M+ - SPh - CH2CO), 327, 219, 218, 176,
91 (100); accurate mass 425.1717, calcd for C23H25N2O5 (M+ - SPh)